Genomic Study of Cutis Tricolor (Cutis Tricolor)

It's a study on Syndromic or Isolated Cutis Tricolor and had as main goal to identify the associated gene to the disease thanks to genetic analysis on minors patients and their parents reach by cutis Tricolor or not.

Study Overview

• Status: Not yet recruiting
• Conditions: Pigmentary; Dermatosis
• Intervention / Treatment: Biological: Blood sample; Biological: Cutaneous biopsy; Genetic: High troughput sequencing of human's exome

Detailed Description

Cutis Tricolor (CT) is a rare cutaneous anomaly defined by pigmentary disorders associating large hyper- and hypopigmented macules of immediate proximity, selectively affecting the trunk. CT can be isolated, sporadic or integrated as a complex syndromic form such as Ruggieri-Happle syndrome (RHS) or various forms of pigmentovascular phacomatosis. A recent analysis of one case of RHS followed by CHU of Montpellier by whole exome sequencing allows the identification of a frameshift pathogen variant (heterozygous state) of a candidate gene.

The main objective is to confirm the association of the candidate gene with syndromic CT (SCT, Ruggierri-Happle syndrome) and non syndromic CT, from a genetic molecular blood and biopsy analysis of patients reach by CT and their parents presenting the disease or not. Furthermore, other objectives are to identify others associated candidates genes and to know better cutaneous pigmentary troubles factors, neurologics and eye abnormalities by identifying the differents cellulars pathways particularly the inflammatory pathway in the pathology of SCT.

First of all, it will have a pre-inclusion visit where Dr WILLEMS. M (Clinical Genetic Department - CHU Montpellier, France) and Pr BESSIS. D (Dermatology Department - CHU Montpellier, France) will explain the study's progress. Then, during the inclusion visit, families will sign inform consent for inclusion in the study. The same day, datas will be collected on demographic, clinical datas, including (i) a description of cutaneous, morphologic and extra-cutaneous anomalies and (ii) a cutaneous biopsy and (iii) a blood test will be done.

The genetics exams results will be return to patients during an usual follow-up visit, 12 months after their inclusion in the study.

• Study Type: Interventional
• Enrollment (Estimated): 10
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Didier BESSIS, Prof.; Phone Number: 04 67 33 69 06; Email: d-bessis@chu-montpellier.fr
• Study Contact Backup: Name: Marjolaine WILLEMS, Dr; Phone Number: 04 67 33 65 64; Email: m-willems@chu-montpellier.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with Cutis Tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents)
• Age : from 4 to 60 years

Exclusion Criteria:

• Refusal to sign the informed consent
• Patient who doesn't have a social security scheme or beneficiary of such a scheme
• Pregnant or breastfeeding women
• Patient whith a legal protection measure (guardianship, curatorship)
• Patient under legal protection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: Cutis Tricolor patient included in trio or duo; Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)

Biological: Blood sample; 7.5 mL will be sampled on EDTA tube for each patient; Biological: Cutaneous biopsy; 4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients; Genetic: High troughput sequencing of human's exome; Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients in whom a pathogenic or probably pathogenic variant has been identified by exome sequencing	12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of patients in whom a pathogenic or probably pathogenic variant in the same gene as another patient in the series has been identified	12 months

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Collaborators: IntegraGen SA

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2023
• Primary Completion (Estimated): October 1, 2024
• Study Completion (Estimated): March 1, 2025

Study Registration Dates

• First Submitted: May 19, 2023
• First Submitted That Met QC Criteria: October 3, 2023
• First Posted (Estimated): October 9, 2023

Study Record Updates

• Last Update Posted (Estimated): October 9, 2023
• Last Update Submitted That Met QC Criteria: October 3, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases
• Other Study ID Numbers: RECHMPL22_0029

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No